Deucravacitinib-hydrochloride-BMS-986165-hydrochloride-生命科學(xué)試劑-MCE

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEDeucravacitinibhydrochlorideCat.No.:HY-117287ACASNo.:1609392-28-0Synonyms:BMS-986165hydrochloride分?式:C??H??D?ClN?O?分?量:461.92作?靶點:InterleukinRelated;JAK;IFNAR作?通路:Immunology/Inflammation;Epigenetics;JAK/STATSignaling;ProteinTyrosineKinase/RTK;StemCell/Wnt儲存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性Deucravacitinibhydrochloride(BMS-986165hydrochloride)?種?度選擇性的全位點抑制劑，具有對TYK2的強效抑制活性。Deucravacitinibhydrochloride能夠有效阻斷IL-12、IL-23和Ⅰ型?擾素信號傳導(dǎo)。Deucravacitinibhydrochloride在炎癥性腸病的前臨床模型中展現(xiàn)出顯著的療效。Deucravacitinibhydrochloride與安慰劑和apremilast相?，在中度?重度斑塊型銀屑病的多個療效終點上表現(xiàn)出優(yōu)勢。Deucravacitinibhydrochloride在抑制中被良好耐受。戶使?本產(chǎn)品發(fā)表的科研?獻?NatChemBiol.2022Dec;18(12):1388-1398.?CellDeathDiffer.2021Feb;28(2):748-763.?MolSystBiol.2023Dec18.?IntJMolSci.2023May25,24(11),9243.?IntJMolSci.2022May1;23(9):5040.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].WrobleskiST,etal.HighlySelectiveInhibitionofTyrosineKinase2(TYK2)fortheTreatmentofAutoimmuneDiseases:DiscoveryoftheAllostericInhibitorBMS-986165.JMedChem.2019Jul18.1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE[2].CatlettI,etal.SAT0226Afirst-in-human,studyofBMS-986165,aselective,potent,allostericsmallmoleculeinhibitoroftyrosinekinase2.AnnalsoftheRheumaticDiseases2017;76:859.[3].Deucravacitinibversusplaceboandapremilastinmoderatetosevereplaquepsoriasis:Efficacyandsafetyresultsfromthe52-week,randomized,double-blinded,placebo-controlledphase3POETYKPSO-1trialMcePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;0